UNASSIGNED:本研究的目的是评估经导管主动脉瓣置换术后5-m步行测试是否与1年死亡率相关。
UNASSIGNED:分析中包括2012年9月至2019年3月接受5米步行测试并接受经导管主动脉瓣置换术的304例患者。根据他们的测试分数将他们分为3组:≤7、>7和不能行走。术前特征,术后结果,并比较两组间的随访结果.
UNASSIGNED:对于5米步行测试,145分≤7(N组),111的得分>7(S组),48人无法行走(第一组)。N组的平均年龄为80.2±8.7岁,S组81.2±9.4年,第一组为79.4±9.2(P=0.23)。N组患者出院时主动脉瓣平均压差为9.5±4.1mmHg,S组10.4±5.5mmHg,第一组为8.2±4.2mmHg(P=0.05)。N组出院生存率为97.2%,S组96.4%,第一组为95.8%(P=0.76)。N组一年生存率为92.8%,S组中84.1%,在调整术前特征后,第一组为75%(P<0.01)。N组非心源性死亡为5.1%,S组中13.1%,第一组为22.7%(P=0.03)。这表明5-m步行测试是1年死亡率的危险因素。更具体地说,5-m步行测试评分较差与1年非心源性死亡率相关.
UNASSIGNED:经导管主动脉瓣置换术前的5米步行测试评分与1年死亡率相关,尤其是非心源性死亡率。它可能有助于识别1年死亡率高的患者。
UNASSIGNED: The purpose of this study is to assess whether the 5-m walk test is associated with 1-year mortality after transcatheter aortic valve replacement.
UNASSIGNED: Included in the analysis were 304 patients who received the 5-m walk test and underwent transcatheter aortic valve replacement from September 2012 to March 2019. They were classified into 3 groups based on their test score: ≤7, >7, and unable to walk. Preprocedure characteristics, postprocedure outcomes, and follow-up outcomes were compared between the groups.
UNASSIGNED: For the 5-m walk test, 145 had a score ≤7 (Group N), 111 had a score >7 (Group S), and 48 were unable to walk (Group I). Average age in years was 80.2 ± 8.7 years in Group N, 81.2 ± 9.4 years in Group S, and 79.4 ± 9.2 in Group I (P = .23). The aortic valve mean gradient at discharge was 9.5 ± 4.1 mm Hg in Group N, 10.4 ± 5.5 mm Hg in Group S, and 8.2 ± 4.2 mm Hg in Group I (P = .05). The discharge survival was 97.2% in Group N, 96.4% in Group S, and 95.8% in Group I (P = .76). One-year survival was 92.8% in Group N, 84.1% in Group S, and 75% in Group I (P < .01) after adjusting for preprocedure characteristics. Noncardiac death was 5.1% in Group N, 13.1% in Group S, and 22.7% in Group I (P = .03). This indicates that the 5-m walk test was a risk factor for 1-year mortality. More specifically, a poor 5-m walk test score was associated with 1-year noncardiac mortality.
UNASSIGNED: The 5-m walk test score before transcatheter aortic valve replacement was associated with 1-year mortality, especially noncardiac mortality. It may help identify patients at high risk for 1-year mortality.